The N-terminal integrity is critical for the stability and biological functions of endostatin

Biochemistry

Volumn 49, Issue 30, 2010, Pages 6420-6429

  Fu, Yan ^a   Luo, Yongzhang ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID RESIDUES; ANGIOGENESIS INHIBITORS; ANTI-TUMOR ACTIVITIES; ANTI-TUMORS; BINDING CAPACITIES; BINDING PEPTIDE; BINDING RESIDUES; BIOLOGICAL ACTIVITIES; BIOLOGICAL FUNCTIONS; CLINICAL TRIAL; COOPERATIVITY; ENDOSTATINS; FOUR AMINO ACIDS; IN-VITRO; N-TERMINAL TRUNCATION; N-TERMINALS; P. PASTORIS; PICHIA PASTORIS; RECOMBINANT ENDOSTATIN; TERTIARY STRUCTURES; THERAPEUTIC EFFICACY; WILD TYPES; ZINC IONS;

BIOACTIVITY; BIOLOGICAL SYSTEMS; METABOLISM; ORGANIC ACIDS; THERMODYNAMIC STABILITY; THERMODYNAMICS; UREA; ZINC;

AMINO ACIDS;

ENDOSTATIN; UREA;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEWIS CARCINOMA; MOUSE; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; THERMODYNAMICS; TUMOR GROWTH; TUMOR VASCULARIZATION; WILD TYPE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BINDING SITES; ENDOSTATINS; PICHIA; PROTEIN STABILITY; SEQUENCE DELETION; STRUCTURE-ACTIVITY RELATIONSHIP; ZINC;

PICHIA PASTORIS;

EID: 77955024453     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi100489x     Document Type: Article

References (41)

1. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth Cell 88, 277-285
2. Sim, B. K., Fogler, W. E., Zhou, X. H., Liang, H., Madsen, J. W., Luu, K., O'Reilly, M. S., Tomaszewski, J. E., and Fortier, A. H. (1999) Zinc ligand-disrupted recombinant human endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile Angiogenesis 3, 41-51
3. Boehm, T., O'Reilly, M. S., Keough, K., Shiloach, J., Shapiro, R., and Folkman, J. (1998) Zinc-binding of endostatin is essential for its antiangiogenic activity Biochem. Biophys. Res. Commun. 252, 190-194
4. Herbst, R. S., Hess, K. R., Tran, H. T., Tseng, J. E., Mullani, N. A., Charnsangavej, C., Madden, T., Davis, D. W., McConkey, D. J., O'Reilly, M. S., Ellis, L. M., Pluda, J., Hong, W. K., and Abbruzzese, J. L. (2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors J. Clin. Oncol. 20, 3792-3803
5. Thomas, J. P., Arzoomanian, R. Z., Alberti, D., Marnocha, R., Lee, F., Friedl, A., Tutsch, K., Dresen, A., Geiger, P., Pluda, J., Fogler, W., Schiller, J. H., and Wilding, G. (2003) Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors J. Clin. Oncol. 21, 223-231
6. Perletti, G., Concari, P., Giardini, R., Marras, E., Piccinini, F., Folkman, J., and Chen, L. (2000) Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors Cancer Res. 60, 1793-1796
7. Feldman, A. L., Alexander, H. R., Hewitt, S. M., Lorang, D., Thiruvathukal, C. E., Turner, E. M., and Libutti, S. K. (2001) Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors J. Natl. Cancer Inst. 93, 1014-1020
8. Pawliuk, R., Bachelot, T., Zurkiya, O., Eriksson, A., Cao, Y. H., and Leboulch, P. (2002) Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells Mol. Ther. 5, 345-351
9. Marshall, E. (2002) Setbacks for endostatin Science 295, 2198-2199
10. Kulke, M. H., Bergsland, E. K., Ryan, D. P., Enzinger, P. C., Lynch, T. J., Zhu, A. X., Meyerhardt, J. A., Heymach, J. V., Fogler, W. E., Sidor, C., Michelini, A., Kinsella, K., Venook, A. P., and Fuchs, C. S. (2006) Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors J. Clin. Oncol. 24, 3555-3561 (Pubitemid 46630526)
11. Hohenester, E., Sasaki, T., Olsen, B. R., and Timpl, R. (1998) Crystal structure of the angiogenesis inhibitor endostatin at 1.5 angstrom resolution EMBO J. 17, 1656-1664
12. Ding, Y. H., Javaherian, K., Lo, K. M., Chopra, R., Boehm, T., Lanciotti, J., Harris, B. A., Li, Y., Shapiro, R., Hohenester, E., Timpl, R., Folkman, J., and Wiley, D. C. (1998) Zinc-dependent dimers observed in crystals of human endostatin Proc. Natl. Acad. Sci. U.S.A. 95, 10443-10448
13. Hohenester, E., Sasaki, T., Mann, K., and Timpl, R. (2000) Variable zinc coordination in endostatin J. Mol. Biol. 297, 1-6
14. Han, Q., Fu, Y., Zhou, H., He, Y. B., and Luo, Y. Z. (2007) Contributions of Zn(II)-binding to the structural stability of endostatin FEBS Lett. 581, 3027-3032
15. Tjin, R. M., Sjin, T., Satchi-Fainaro, R., Birsner, A. E., Ramanujam, V. M. S., Folkman, J., and Javaherian, K. (2005) A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity Cancer Res. 65, 3656-3663
16. Eder, J. P., Supko, J. G., Clark, J. W., Puchalski, T. A., Garcia-Carbonero, R., Ryan, D. P., Shulman, L. N., Proper, J., Kirvan, M., Rattner, B., Connors, S., Keogan, M. T., Janicek, M. J., Fogler, W. E., Schnipper, L., Kinchla, N., Sidor, C., Phillips, E., Folkman, J., and Kufe, D. W. (2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily J. Clin. Oncol. 20, 3772-3784
17. Yang, L., Wang, J., Tang, Z., Liu, X., Huang, J., Li, S., Dong, Y., Zhang, H., Xue, L., Chu, D., and Sun, Y. (2004) A phase I clinical trial for recombinant human endostatin Zhongguo Xinyao Zazhi 13, 6
18. Yang, L., Jinwan, W., Yan, S., Yunzhong, Z., Liu, X., Li, W., Di, L., Li, P., Wang, Y., Song, S., Yao, C., and You, L. (2006) Randomized Phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer Chin. J. Oncol. 28, 4
19. Yang, L., Wang, J. W., Cui, C., Huang, J., Zhang, H., Li, S., and Sun, Y. (2005) Rh-endostatin (YH-16) in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer: A multicenter phase II trial Zhongguo Xinyao Zazhi 14, 4
20. Wang, J. W., Sun, Y., Liu, Y., Yu, Q., Zhang, Y., Li, K., and Zhu, Y. (2005) Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients Zhongguo Feiai Zazhi 8, 8
21. Shi, H. B., Huang, Y. J., Zhou, H., Song, X. M., Yuan, S. P., Fu, Y., and Luo, Y. Z. (2007) Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin Blood 110, 2899-2906
22. Huang, Y. J., Shi, H. B., Zhou, H., Song, X. M., Yuan, S. P., and Luo, Y. Z. (2006) The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin Blood 107, 3564-3571
23. Ades, E. W., Candal, F. J., Swerlick, R. A., George, V. G., Summers, S., Bosse, D. C., and Lawley, T. J. (1992) HMEC-1: Establishment of an immortalized human microvascular endothelial cell line J. Invest. Dermatol. 99, 683-690
24. Edelhoch, H. (1967) Spectroscopic determination of tryptophan and tyrosine in proteins Biochemistry 6, 1948-1954
25. Fu, Y., Wu, X., Han, Q., Liang, Y., He, Y., and Luo, Y. (2008) Sulfate stabilizes the folding intermediate more than the native structure of endostatin Arch. Biochem. Biophys. 471, 232-239
26. Fu, Y., Chen, Y., Luo, X., Liang, Y., Shi, H. B., Gao, L., Zhan, S. L., Zhou, D. F., and Luo, Y. Z. (2009) The Heparin Binding Motif of Endostatin Mediates Its Interaction with Receptor Nucleolin Biochemistry 48, 11655-11663
27. Santoro, M. M. and Bolen, D. W. (1988) Unfolding free energy changes determined by the linear extrapolation method. 1. Unfolding of phenylmethanesulfonyl α-chymotrypsin using different denaturants Biochemistry 27, 8063-8068
28. Luo, Y., Kay, M. S., and Baldwin, R. L. (1997) Cooperativity of folding of the apomyoglobin pH 4 intermediate studied by glycine and proline mutations Nat. Struct. Biol. 4, 925-930
29. Li, B., Wu, X. Y., Zhou, H., Chen, Q. J., and Luo, Y. Z. (2004) Acid-induced unfolding mechanism of recombinant human endostatin Biochemistry 43, 2550-2557
30. Wu, X. Y., Huang, J., Chang, G. D., and Luo, Y. Z. (2004) Detection and characterization of an acid-induced folding intermediate of endostatin Biochem. Biophys. Res. Commun. 320, 973-978
31. Zhou, H., Wang, W., and Luo, Y. Z. (2005) Contributions of disulfide bonds in a nested pattern to the structure, stability, and biological functions of endostatin J. Biol. Chem. 280, 11303-11312
32. Ogunlewe, J. O. and Osegbe, D. N. (1989) Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate Cancer 63, 1388-1392
33. Santucci, R., Ascoli, F., Amiconi, G., Bertollini, A., and Brunori, M. (1985) Conformational-Changes Induced by Polyanions in Hemoglobin from Camelus dromedarius: Circular-Dichroism Study on the Oxy Derivative Biochem. J. 231, 793-796
34. Lelj-Garolla, B. and Mauk, A. G. (2006) Self-association and chaperone activity of Hsp27 are thermally activated J. Biol. Chem. 281, 8169-8174
35. Lebowitz, J., Lewis, M. S., and Schuck, P. (2002) Modern analytical ultracentrifugation in protein science: A tutorial review Protein Sci. 11, 2067-2079
36. Gloss, L. M. and Matthews, C. R. (1997) Urea and thermal equilibrium denaturation studies on the dimerization domain of Escherichia coli Trp repressor Biochemistry 36, 5612-5623
37. Celik, I., Surucu, O., Dietz, C., Heymach, J. V., Force, J., Hoschele, I., Becker, C. M., Folkman, J., and Kisker, O. (2005) Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve Cancer Res. 65, 11044-11050
38. Boehm, T., Folkman, J., Browder, T., and OReilly, M. S. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390, 404-407
39. Huang, X., Wong, M. K., Zhao, Q., Zhu, Z., Wang, K. Z., Huang, N., Ye, C., Gorelik, E., and Li, M. (2001) Soluble recombinant endostatin purified from Escherichia coli: Antiangiogenic activity and antitumor effect Cancer Res. 61, 478-481
40. Toonkool, P., Metheenukul, P., Sujiwattanarat, P., Paiboon, P., Tongtubtim, N., Ketudat-Cairns, M., Ketudat-Cairns, J., and Svasti, J. (2006) Expression and purification of dalcochinase, a β-glucosidase from Dalbergia cochinchinensis Pierre, in yeast and bacterial hosts Protein Expression Purif. 48, 195-204
41. Jia, H. and Kling, J. (2006) China offers alternative gateway for experimental drugs Nat. Biotechnol. 24, 117-118